AI Article Synopsis
- A scalable synthesis process for the preclinical drug candidate DNDI-VL-2098, aimed at treating visceral leishmaniasis, is outlined.
- The synthesis involves a four-step method, including the Sharpless asymmetric epoxidation of 2-methyl-2-propen-1-ol and utilizes retrosynthetic analysis to optimize the route.
- The process is streamlined by using in situ synthesis for intermediates, which enhances safety and eliminates the need for column chromatography, resulting in high yields and purity on a kilogram scale.
Article Abstract
A process suitable for kilogram-scale synthesis of (2)-2-methyl-6-nitro-2-{[4-(trifluoromethoxy)phenoxy]methyl}-2,3-dihydroimidazo[2,1-][1,3]oxazole (DNDI-VL-2098, ), a preclinical drug candidate for the treatment of visceral leishmaniasis, is described. The four-step synthesis of the target compound involves the Sharpless asymmetric epoxidation of 2-methyl-2-propen-1-ol, . Identification of a suitable synthetic route using retrosynthetic analysis and development of a scalable process to access several kilograms of are illustrated. The process was simplified by employing in situ synthesis of some intermediates, reducing safety hazards, and eliminating the need for column chromatography. The improved reactions were carried out on the kilogram scale to produce in good yield, high optical purity, and high quality.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5437808 | PMC |
| http://dx.doi.org/10.1021/acs.oprd.6b00331 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!